Evidence map›Paper›PMID 38622285›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2024

Integration of multiomics analyses reveals unique insights into CD24-mediated immunosuppressive tumor microenvironment of breast cancer.

Haihong Hu, Hongxia Zhu, Wendi Zhan, Bo Hao, Ting Yan, Jingdi Zhang, Siyu Wang, Xuefeng Xu, Taolan Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 citations in OpenAlex.

  1. Potentiating mild photothermal therapy via CDK12/13-mediated AKT suppression to orchestrate ferroptosis-apoptosis crosstalk for vaccine-like immunity.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Haihong Hu *Department of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Hongxia Zhu *Department of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Wendi Zhan *Department of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Bo HaoDepartment of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Ting YanDepartment of Breast and Thyroid Surgery, The First Affiliated HospitalH, engyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Jingdi ZhangDepartment of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Siyu WangDepartment of Medical Oncology,The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Xuefeng Xu *Department of Function, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Taolan Zhang *Department of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. TaolZhan@usc.edu.cn.ORCID http://orcid.org/0000-0002-0049-128X
University of South China · CNFirst Affiliated Hospital of University of South China · CN

Funding

China Scholarship Council 201808430085Clinical Research 4310 Program of the First Affiliated Hospital of the University of South China 20224310NHYCG04National Natural Science Foundation of China 82003802Natural Science Foundation of Hunan Province 2019JJ50542 and 2023JJ50156Natural Science Foundation of Hunan Province 2024JJ7455Science and technology innovation Program of Hengyang City 202250045223Science and Technology Program of Hunan Health Commission 20201978
6 · The paper itself

Abstract

backgroundTumor immunotherapy brings new light and vitality to breast cancer patients, but low response rate and limitations of therapeutic targets become major obstacles to its clinical application. Recent studies have shown that CD24 is involved in an important process of tumor immune regulation in breast cancer and is a promising target for immunotherapy.

methodsIn this study, singleR was used to annotate each cell subpopulation after t-distributed stochastic neighbor embedding (t-SNE) methods. Pseudo-time trace analysis and cell communication were analyzed by Monocle2 package and CellChat, respectively. A prognostic model based on CD24-related genes was constructed using several machine learning methods. Multiple quantitative immunofluorescence (MQIF) was used to evaluate the spatial relationship between CD24

resultsBased on the scRNA-seq analysis, 1488 CD24-related differential genes were identified, and a risk model consisting of 15 prognostic characteristic genes was constructed by combining the bulk RNA-seq data. Patients were divided into high- and low-risk groups based on the median risk score. Immune landscape analysis showed that the low-risk group showed higher infiltration of immune-promoting cells and stronger immune reactivity. The results of cell communication demonstrated a strong interaction between CD24

conclusionThis study highlights the importance of CD24

Indexed as

Breast NeoplasmsCD24 AntigenTumor MicroenvironmentCD8-Positive T-LymphocytesFemaleHumansMachine LearningMultiomicsPrognosisCD24 AntigenCD24 protein, humanBreast cancerCD24CD8+T cellImmunotherapyTumor immune microenvironment

Identifiers

PMID38622285
OpenAlexW4394820737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.